Related Experiment Videos
Virus-like particles as a rotavirus subunit vaccine
1Division of Molecular Virology, Baylor College of Medicine, Houston, Texas, USA.
The Journal of Infectious Diseases
|September 1, 1996
Summary
Rotavirus virus-like particle (VLP) vaccines show promise for human use. Parenteral administration in animal models induced protective immunity against rotavirus, suggesting VLP efficacy as a subunit vaccine.
Area of Science:
- Virology
- Immunology
- Vaccine Development
Background:
- Rotavirus is a leading cause of severe diarrheal disease in infants globally.
- Current rotavirus vaccines are live-attenuated, and subunit vaccines are under development.
- Virus-like particles (VLPs) are a promising platform for subunit vaccine production.
Purpose of the Study:
- To evaluate the immunogenicity and protective efficacy of rotavirus virus-like particle (VLP) vaccines.
- To assess VLP vaccine potential for human rotavirus subunit vaccine applications.
Main Methods:
- VLPs were produced in insect cells using baculovirus expression systems.
- VLPs incorporated rotavirus proteins (VP2, VP4, VP6, VP7).
- Parenteral vaccination was performed in mice and rabbits, followed by rotavirus challenge.
Main Results:
- Rabbits developed high levels of rotavirus-specific serum IgG and fecal IgG.
- Fecal IgG correlated with protection against rotavirus challenge.
- Mice showed heterotypic neutralizing antibody responses after VLP vaccination.
- VLPs formulated with QS21 adjuvant induced high serum neutralizing antibody titers.
Conclusions:
- Rotavirus VLPs are effective parenteral immunogens.
- VLP-based vaccines demonstrate potential for inducing protective immunity against rotavirus.
- Further development of VLP vaccines is warranted for human rotavirus prevention.